Lenalidomide maintenance after autologous HSCT
EFS indicates event-free survival (includes deaths, progressions, and second cancers); IT, intensive therapy; NIT, nonintensive therapy; and ND, no difference.
Adapted from McCarthy et al.42
Sign In or Create an Account